Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
NCT07874334Phase 1Not yet recruiting
- Sponsor
- Hadassah Medical Organization
- Start
- Nov 2026
- Primary completion
- Dec 2032
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in multiple myeloma (MM) and light-chain amyloidosis, sponsored by Hadassah Medical Organization. Primary endpoints: Incidence of Treatment-Related Serious Adverse Events and Adverse Events of Special Interest at 24 months and Maximum tolerated dose at 21 days. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
multiple myeloma (MM)light-chain amyloidosis
Beyond the preview
Go deeper on NCT07874334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874334.